53512 Federal Register / Vol. 82, No. 220 / Thursday, November 16, 2017 / Notices 

433: Support of NIGMS Program Project 

Grants. 

Date: November 29, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Eduardo A. Montalvo, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5108, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1168, montalve@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: AIDS and Related Research. 

Date: December 1, 2017. 

Time: 3:00 p.m. to 3:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Robert Freund, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5216, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1050, freundr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR Panel: 

AIDS and AIDS-Related Research. 

Date: December 7, 2017. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Robert Freund, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5216, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1050, freundr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Developmental Abnormalities of the 

Nervous System. 

Date: December 8, 2017. 

Time: 2:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Suzan Nadi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5217B, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1259, nadis@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR17–031: 

Role of Age-Associated Metabolic Changes in 

Alzheimer’s Disease. 

Date: December 13, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Alessandra C Rovescalli, 

Ph.D., Scientific Review Officer, National 

Institutes of Health, Center for Scientific 

Review, 6701 Rockledge Drive, Rm. 5205, 

MSC 7846, Bethesda, MD 20892, (301) 435– 

1021, rovescaa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 9, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24759 Filed 11–15–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Division of Intramural 

Research Board of Scientific Counselors, 

NIAID. The meeting will be closed to 

the public as indicated below in 

accordance with the provisions set forth 

in section 552b(c)(6), Title 5 U.S.C., as 

amended for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Institute of Allergy and 

Infectious Diseases, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Division of Intramural 

Research Board of Scientific Counselors, 

NIAID. 

Date: December 11–13, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

Building 50, 1227/1233, 50 Center Drive, 

Bethesda, MD 20892. 

Contact Person: Steven M. Holland, MD, 

Ph.D., Chief, Laboratory of Clinical Infectious 

Diseases, National Institutes of Health/ 

NIAID, Hatfield Clinical Research Center, 

Bethesda, MD 20892–1684, 301–402–7684, 

sholland@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: November 9, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–24761 Filed 11–15–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

Commercialization License: Direct 

Reading Detection Kits for Surface 

Contamination by Antineoplastic 

Drugs 

AGENCY: Centers for Disease Control and 

Prevention, National Institutes of 

Health. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases, an 

institute of the National Institutes of 

Health, Department of Health and 

Human Services, on behalf of the 

Centers for Disease Control and 

Prevention, Department of Health and 

Human Services, is contemplating the 

grant of an exclusive patent 

commercialization license to Becton, 

Dickinson and Company, located in 

Franklin Lakes, New Jersey, to practice 

the inventions embodied in the patent 

applications listed in the 

Supplementary Information section of 

this notice. 

DATES: Only written comments and/or 

applications for a license which are 

received by the Technology Transfer 

and Intellectual Property Office, 

National Institute of Allergy and 

Infectious Diseases on or before 

December 1, 2017 will be considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

exclusive patent commercialization 

license should be directed to: Karen 

Surabian, Licensing and Patenting 

Manager, Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Suite 2G, 

MSC9804, Rockville, MD 20852–9804, 

phone number 301–594–9719, or 

karen.surabian@nih.gov. 

SUPPLEMENTARY INFORMATION: The 

following represents the intellectual 

property to be licensed under the 

prospective agreement: HHS Reference 

No. E–162–2013/0–US–01, United 

States Provisional Patent Application 

Serial Number 61/672,059, filed 07/16/ 

2012; HHS Reference No. E–162–2013/ 

0–PCT–02, PCT Patent Application 


asabaliauskas on DSKBBXCHB2PROD with NOTICES